Core Viewpoint - Shineco, Inc. has announced a 50:1 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective August 11, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert fifty current shares into one new share, with any fractional shares rounded up to the next whole share [3]. - The number of outstanding shares is expected to decrease from approximately 45,722,728 to about 914,455 shares, subject to adjustments for fractional shares [4]. - Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards and incentive plans [4]. Group 2: Compliance and Listing - The reverse stock split aims to bring the Company into compliance with Nasdaq's minimum bid price requirement, although there is no guarantee that the stock price will remain above the required level for continued listing [2]. - The Company’s Common Stock will continue to trade under the symbol "SISI" on the Nasdaq Capital Market following the split [1]. Group 3: Stockholder Information - Stockholders holding shares in book-entry form will not need to take action to receive their post-split shares [5]. - Stockholders with pre-split certificates will receive a letter of transmittal with instructions on how to surrender their certificates [6].

Core Viewpoint - Shineco, Inc. announces a stock purchase program led by CEO Jennifer Zhan and CFO Sam Wang, intending to buy up to $2,000,000 of the company's common stock, reflecting their belief that the stock is undervalued [1][3]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health products [3]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, in addition to producing and selling healthy and nutritious foods [3]. Stock Purchase Program Details - The stock purchase program will involve open market purchases funded by the personal cash of Ms. Zhan and Mr. Wang, with a maximum purchase price of $1.50 per share [1][2]. - The timing and number of shares purchased will depend on various factors, including the company's business conditions and stock pricing [2]. Management's Perspective - CEO Jennifer Zhan emphasizes that the insider-led purchase initiative reflects management's confidence in Shineco's long-term growth potential and the belief that the current stock price does not accurately reflect the company's technological advantages and market potential [3].

Core Viewpoint - Shineco, Inc. has announced the acquisition of a 51% equity interest in InfiniClone Limited, a biotechnology company specializing in regenerative medicine, marking a significant step into the stem cell technology sector [2][3][6]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health solutions [7]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, alongside producing and selling healthy foods [7]. Acquisition Details - The acquisition involves a payment of $19,895,600 in cash and the issuance of 3,450,000 shares of common stock to the seller, Dr. Lim Kah Meng [3]. - InfiniClone holds 29 global patents, including five invention patents, which cover major markets such as the US, Europe, and Asia, providing a competitive edge in stem cell technology [4]. InfiniClone's Technology - InfiniClone's core technologies include cell reprogramming, stem cell culture using microcarrier technology, and the management of induced pluripotent stem cell (iPSC) libraries, which can enhance cell expansion throughput by three to ten times compared to existing methods [4]. - The technology is expected to reduce production costs per cell by over 60% and significantly shorten the time required for clinical applications, such as treating Parkinson's and Alzheimer's diseases [4]. Leadership and Expertise - Dr. Lim Kah Meng, the founder of InfiniClone, has over 20 years of experience in molecular research related to stem cell and regenerative medicine, and has founded several biotechnology companies [5]. - Shineco's CEO, Jennifer Zhan, emphasized the acquisition as a key milestone for entering the regenerative medicine field and highlighted the potential for transforming InfiniClone's technology from laboratory to clinical applications [6].